Autoimmune toxicities associated with the administration of antitumor vaccines and low-dose interleukin-2.
about
Toxicities of Immunotherapy for the PractitionerInflammatory adverse events are associated with disease-free survival after vaccine therapy among patients with melanoma.Cytokines as Adjuvants for Vaccine and Cellular Therapies for Cancer.Combined stimulation of IL-2 and 4-1BB receptors augments the antitumor activity of E7 DNA vaccines by increasing Ag-specific CTL responses.Phase Ib trial assessing autologous, tumor-pulsed dendritic cells as a vaccine administered with or without IL-2 in patients with metastatic melanomaImmunoproteasomes and immunotherapy-a smoking gun for lung cancer?Opportunistic autoimmune disorders: from immunotherapy to immune dysregulationThe yin and yang of immunomodulatory biologics: assessing the delicate balance between benefit and risk.Protein and non-protein biomarkers in melanoma: a critical update.Pembrolizumab Therapy Triggering an Exacerbation of Preexisting Autoimmune Disease: A Report of 2 Patient CasesThe Society for Immunotherapy of Cancer consensus statement on tumour immunotherapy for the treatment of cutaneous melanoma.Improved survival and tumor control with Interleukin-2 is associated with the development of immune-related adverse events: data from the PROCLAIMSM registry.Thyroid dysfunctions secondary to cancer immunotherapy.Taking a Stab at Cancer; Oncolytic Virus-Mediated Anti-Cancer Vaccination Strategies.
P2860
Q27008140-3437AC92-FB65-420B-B8EF-D6283071B359Q30370026-8F5D9B1D-69DE-47A0-A864-00F72416D803Q33680566-03BB77C3-B7EA-48FA-83E0-F7E2778B9FB8Q35082617-618D767E-1623-435B-9A18-AF9ED441C4A0Q37096944-45CD9DD0-472E-4DFB-B47C-F178AE6C58C5Q37121401-C30B6552-813E-40DC-B282-CFC7B0DEC0A4Q37274049-0CCB5278-AC31-44B2-86B4-6E2D3A052136Q37973651-EA228CC2-BE6B-4F50-A8DE-0AEC20589505Q38050990-B75C67AE-15CE-40C0-8752-0189422D234FQ39003398-1A3BC18C-6721-4A80-B5AE-0383B205663AQ43556611-F81E7D52-45DC-49C3-AEE8-9D10DEF79090Q47287952-FD93E836-CF08-40B3-B501-48350F5B5771Q47565857-A9B600E5-2629-41DE-A98B-34CAC2BAB291Q55085319-9A904696-B111-4A7A-A3A2-422270D51F92
P2860
Autoimmune toxicities associated with the administration of antitumor vaccines and low-dose interleukin-2.
description
2005 nî lūn-bûn
@nan
2005 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
Autoimmune toxicities associat ...... es and low-dose interleukin-2.
@ast
Autoimmune toxicities associat ...... es and low-dose interleukin-2.
@en
type
label
Autoimmune toxicities associat ...... es and low-dose interleukin-2.
@ast
Autoimmune toxicities associat ...... es and low-dose interleukin-2.
@en
prefLabel
Autoimmune toxicities associat ...... es and low-dose interleukin-2.
@ast
Autoimmune toxicities associat ...... es and low-dose interleukin-2.
@en
P2093
P1476
Autoimmune toxicities associat ...... es and low-dose interleukin-2.
@en
P2093
Elizabeth M H Woodson
Gina R Petroni
Huimin Tao
Mark Smolkin
Patrice Y Neese
Priscilla Merrill
Scott A Boerner
William W Grosh
P304
P356
10.1097/01.CJI.0000171314.00924.2B
P577
2005-07-01T00:00:00Z